Alzheimer's drug prescribed off-label could pose risk for some

Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation - the K-variant of butyrylcholinesterase, or BChE-K - donezpezil could accelerate cognitive decline.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news